Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Sober Start as Recreational Marijuana Becomes Legal in Canada

Published: Thu, 18 Oct 2018 11:33:36 EDT
Canada became the first industrialized nation to legalize recreational cannabis on Wednesday, but a lawful buzz will be hard to come by in its biggest cities like Toronto and Vancouver, where stores are not yet open.
Reuters Health Information

Novel Anti-B-Cell Therapy Looks Promising in MS

Published: Thu, 18 Oct 2018 11:23:17 EDT
A new and novel oral therapy for multiple sclerosis, which inactivates rather than depletes B cells, has shown promising results in its first efficacy study.
Medscape Medical News

AAO 2018

Published: Thu, 18 Oct 2018 10:57:41 EDT
Read clinically focused news coverage of key developments from AAO 2018.
Medscape Ophthalmology

No Chemo; Rituximab Alone for Indolent Lymphoma?

Published: Thu, 18 Oct 2018 10:46:16 EDT
New results showing a 10-year overall survival rate of 73% with rituximab alone suggest that patients can skip chemotherapy. But this may not be appropriate for all patients, suggests an expert.
Medscape Medical News
Displaying results 5-8 (of 20)
 1 - 2 - 3 - 4 - 5 


Johnson & Johnson takes $630M hit on RSV drug bought with Alios

Published: Wed, 17 Oct 2018 20:02:10 +0000
Four years ago, Johnson & Johnson splashed out $1.75 billion to take control of antiviral specialist Alios, but the lead drug from that deal now seems to be in trouble.

Eiger chalks up one win, one loss in rare disease pipeline

Published: Wed, 17 Oct 2018 12:39:39 +0000
Eiger BioPharma has given up on one of its rare disease candidates after a second negative trial, but a midstage win for another drug has more than softened the blow.

Roche sheds clutch of in-licensed drugs in pipeline cull

Published: Wed, 17 Oct 2018 12:24:07 +0000
The most advanced drug to get the chop is RG6125, an anti-cadherin 11 antibody that entered a phase 2 rheumatoid arthritis trial last year.

Pharnext muscle wasting phase 3 hits primary endpoint

Published: Wed, 17 Oct 2018 11:57:34 +0000
A phase 3 trial of Pharnext’s PXT3003 in a rare, muscle wasting disease has met its primary endpoint. The trial linked the fixed-dose combination to a statistically significant improvement on a measure of patient disability.
Displaying results 5-8 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy